

IT'S GOOD TO BE SURE



A Breakthrough In Alzheimer's Diagnosis

Accessible Testing Through A Simple Blood Sample
With Over 90% Diagnostic Accuracy



Alzheimer's disease is a progressive neurodegenerative disorder marked by Amyloid- β and tau pathology, resulting in cognitive decline, memory loss, and impaired daily functioning

Why Non Invasive Plasma Biomarkers?



Suitable for routine clinical practice



Enables large scale screening



Personalized disease risk assessment & earlier clinical intervention



Offers patient compliance



pTau217 / β -Amyloid 1-42 Ratio ensures high diagnostic accuracy



More than 90% accuracy in differentiating Alzheimer's disease from non-AD dementias



Strong concordance with Amyloid PET imaging.



Outperforms standalone biomarkers

Alzheimer's Disease/ Dementia Markers

(Reports Plasma pTau217, β -Amyloid 1-42 & pTau217/ β -Amyloid 1-42 Ratio)



Blood-based biomarker testing for Alzheimer's disease



Detects amyloid and tau changes years before symptoms



Predicts progression to dementia with high confidence

Test Code	Test Name	Sample Type	Parameters
D8479	Alzheimer's Disease/ Dementia Markers	Plasma	Reports Plasma pTau217, β -Amyloid 1-42 & pTau217/ β -Amyloid 1-42 Ratio



Also Available:

Alzheimer disease screening Profile- CSF (A0623)



Total Tau, β -Amyloid 1-42, β Amyloid 1-40, β Amyloid ratio (1-42/1-40)

Apolipoprotein (APOE) Genotyping (A0618)



One or two copies of ApoE4 is associated with high risk of developing AD



IT'S GOOD TO BE SURE

Corporate Office: Metropolis Healthcare Limited, 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr., Annie Besant Road, Worli Mumbai - 400030, Maharashtra, India

To book your appointment: Call 8422 801 801 Or visit www.metropolisindia.com

Scan for
Metropolis DOS

